These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 23404126)

  • 21. 244-MPT overcomes gefitinib resistance in non-small cell lung cancer cells.
    Zhang Y; Yao K; Shi C; Jiang Y; Liu K; Zhao S; Chen H; Reddy K; Zhang C; Chang X; Ryu J; Bode AM; Dong Z; Dong Z
    Oncotarget; 2015 Dec; 6(42):44274-88. PubMed ID: 26517520
    [TBL] [Abstract][Full Text] [Related]  

  • 22. ["Targeted Therapies" in NSCLC - present and future].
    Pall G; Hilbe W
    Wien Med Wochenschr; 2007; 157(21-22):545-53. PubMed ID: 18157592
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dacomitinib in lung cancer: a "lost generation" EGFR tyrosine-kinase inhibitor from a bygone era?
    Ou SH; Soo RA
    Drug Des Devel Ther; 2015; 9():5641-53. PubMed ID: 26508839
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment outcomes in elderly with advanced-stage non-small cell lung cancer.
    Tam TC; Ho JC; Wong MK; Wong WM; Wang JK; Lam JC; Lui MM; Lam WK; Ip MS; Lam DC
    Lung; 2013 Dec; 191(6):645-54. PubMed ID: 23929397
    [TBL] [Abstract][Full Text] [Related]  

  • 25. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
    Greenhalgh J; Dwan K; Boland A; Bates V; Vecchio F; Dundar Y; Jain P; Green JA
    Cochrane Database Syst Rev; 2016 May; (5):CD010383. PubMed ID: 27223332
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety and effectiveness of bevacizumab-containing treatment for non-small-cell lung cancer: final results of the ARIES observational cohort study.
    Lynch TJ; Spigel DR; Brahmer J; Fischbach N; Garst J; Jahanzeb M; Kumar P; Vidaver RM; Wozniak AJ; Fish S; Flick ED; Leon L; Hazard SJ; Kosty MP;
    J Thorac Oncol; 2014 Sep; 9(9):1332-9. PubMed ID: 25122429
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sequencing of ALK Inhibitors in ALK+ Non-Small Cell Lung Cancer.
    Gadgeel SM
    Curr Treat Options Oncol; 2017 Jun; 18(6):36. PubMed ID: 28534251
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Next-generation epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor -mutant non-small cell lung cancer.
    Tan CS; Cho BC; Soo RA
    Lung Cancer; 2016 Mar; 93():59-68. PubMed ID: 26898616
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Drug repositioning for non-small cell lung cancer by using machine learning algorithms and topological graph theory.
    Huang CH; Chang PM; Hsu CW; Huang CY; Ng KL
    BMC Bioinformatics; 2016 Jan; 17 Suppl 1(Suppl 1):2. PubMed ID: 26817825
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effectiveness and safety of bevacizumab for unresectable non-small-cell lung cancer: a meta-analysis.
    Yang K; Wang YJ; Chen XR; Chen HN
    Clin Drug Investig; 2010; 30(4):229-41. PubMed ID: 20225906
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Chemotherapy for advanced non-small cell lung cancer with a focus on squamous cell carcinoma.
    Kuribayashi K; Funaguchi N; Nakano T
    J Cancer Res Ther; 2016; 12(2):528-34. PubMed ID: 27461605
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inhibition of non-small cell lung cancer (NSCLC) growth by a novel small molecular inhibitor of EGFR.
    Li J; Deng H; Hu M; Fang Y; Vaughn A; Cai X; Xu L; Wan W; Li Z; Chen S; Yang X; Wu S; Xiao J
    Oncotarget; 2015 Mar; 6(9):6749-61. PubMed ID: 25730907
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The value of tumor markers in evaluating chemotherapy response and prognosis in Chinese patients with advanced non-small cell lung cancer.
    Jin B; Huang AM; Zhong RB; Han BH
    Chemotherapy; 2010; 56(6):417-23. PubMed ID: 21079400
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Development and external validation of prognostic model for 2-year survival of non-small-cell lung cancer patients treated with chemoradiotherapy.
    Dehing-Oberije C; Yu S; De Ruysscher D; Meersschout S; Van Beek K; Lievens Y; Van Meerbeeck J; De Neve W; Rao B; van der Weide H; Lambin P
    Int J Radiat Oncol Biol Phys; 2009 Jun; 74(2):355-62. PubMed ID: 19095367
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Therapeutic management of non-small-cell lung carcinoma (NSCLC) of stage III A].
    Mornex F
    Rev Pneumol Clin; 2001 Nov; 57(5 Pt 2):S29-32. PubMed ID: 11924239
    [No Abstract]   [Full Text] [Related]  

  • 36. The emerging role of histology in the choice of first-line treatment of advanced non-small cell lung cancer: implication in the clinical decision-making.
    Rossi A; Maione P; Bareschino MA; Schettino C; Sacco PC; Ferrara ML; Castaldo V; Gridelli C
    Curr Med Chem; 2010; 17(11):1030-8. PubMed ID: 20156162
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Three-year follow-up results from phase II studies of nivolumab in Japanese patients with previously treated advanced non-small cell lung cancer: Pooled analysis of ONO-4538-05 and ONO-4538-06 studies.
    Horinouchi H; Nishio M; Hida T; Nakagawa K; Sakai H; Nogami N; Atagi S; Takahashi T; Saka H; Takenoyama M; Katakami N; Tanaka H; Takeda K; Satouchi M; Isobe H; Maemondo M; Goto K; Hirashima T; Minato K; Sumiyoshi N; Tamura T
    Cancer Med; 2019 Sep; 8(11):5183-5193. PubMed ID: 31353840
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy of adjuvant chemotherapy for non-small cell lung cancer assessed by metastatic potential associated with ACTN4.
    Miura N; Kamita M; Kakuya T; Fujiwara Y; Tsuta K; Shiraishi H; Takeshita F; Ochiya T; Shoji H; Huang W; Ohe Y; Yamada T; Honda K
    Oncotarget; 2016 May; 7(22):33165-78. PubMed ID: 27121206
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Chemotherapy for advanced non-small cell lung cancer in the elderly population.
    Santos FN; Castria TB; Cruz MR; Riera R
    Sao Paulo Med J; 2016; 134(5):465-466. PubMed ID: 27901246
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In vitro and in vivo therapeutic efficacy of CXCR4 antagonist BKT140 against human non-small cell lung cancer.
    Fahham D; Weiss ID; Abraham M; Beider K; Hanna W; Shlomai Z; Eizenberg O; Zamir G; Izhar U; Shapira OM; Peled A; Wald O
    J Thorac Cardiovasc Surg; 2012 Nov; 144(5):1167-1175.e1. PubMed ID: 22925564
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.